SSEA

Starry Sea is a blank-check shell, not an operating company. By its own 10-K it has "neither engaged in any operations nor generated any revenues to date"; the entire FY2025 net income of $320,643 is interest earned on cash held in the Trust Account ($863,257), partially offset by $542,614 of formation and public-company costs. The $58.7M of total assets is essentially the IPO trust, while operating cash flow is negative (-$703K) and unrestricted cash is just $112K. The reported -$0.78 diluted EPS despite positive GAAP net income reflects accretion on redeemable shares — i.e., there is no real earnings stream to value. At $10.24 the stock sits a hair above the ~$10 per-share trust/redemption value, so the only fundamental "floor" here is the trust, not the business.

The entire thesis now rides on one event: the September 29, 2025 letter of intent to combine with Forever Young International, a China-based operator of management/support services for medical institutions, at a pre-money equity value of roughly $750M–$900M. That is more than ten times the SPAC's current asset base, with consideration paid almost entirely in rollover equity valued at $10/share — meaning legacy SSEA holders would own a tiny slice of a far larger, China-operating entity whose financials, quality, and durability are entirely unknown from this filing. An LOI is non-binding and explicitly "subject to confirmatory due diligence"; it can collapse, reprice, or face redemptions, and China-domiciled reverse-merger structures carry well-documented governance, VIE, and disclosure risks.